401 related articles for article (PubMed ID: 31841727)
1. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F
Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727
[TBL] [Abstract][Full Text] [Related]
2. Prodrugs for nitroreductase based cancer therapy-4: Towards prostate cancer targeting: Synthesis of N-heterocyclic nitro prodrugs, Ssap-NtrB enzymatic activation and anticancer evaluation.
Güngör T; Tokay E; Güven Gülhan Ü; Hacıoğlu N; Çelik A; Köçkar F; Ay M
Bioorg Chem; 2020 Dec; 105():104450. PubMed ID: 33189994
[TBL] [Abstract][Full Text] [Related]
3. Prodrugs for Nitroreductase Based Cancer Therapy- 1: Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB.
Gungor T; Yetis G; Onder FC; Tokay E; Tok TT; Celik A; Ay M; Kockar F
Med Chem; 2018; 14(5):495-507. PubMed ID: 29189173
[TBL] [Abstract][Full Text] [Related]
4. PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
Güngör T; Önder FC; Tokay E; Gülhan ÜG; Hacıoğlu N; Tok TT; Çelik A; Köçkar F; Ay M
Eur J Med Chem; 2019 Jun; 171():383-400. PubMed ID: 30928710
[TBL] [Abstract][Full Text] [Related]
5. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
7. Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
Burke PJ; Wong LC; Jenkins TC; Knox RJ; Meikle IT; Stanforth SP
Bioorg Med Chem Lett; 2016 Dec; 26(24):5851-5854. PubMed ID: 27876476
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
9. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
Mauger AB; Burke PJ; Somani HH; Friedlos F; Knox RJ
J Med Chem; 1994 Oct; 37(21):3452-8. PubMed ID: 7932574
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
11. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
Hay MP; Wilson WR; Denny WA
Bioorg Med Chem Lett; 1999 Dec; 9(24):3417-22. PubMed ID: 10617083
[TBL] [Abstract][Full Text] [Related]
12. An unusually cold active nitroreductase for prodrug activations.
Çelik A; Yetiş G
Bioorg Med Chem; 2012 Jun; 20(11):3540-50. PubMed ID: 22546205
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
14. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
15. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
16. Prodrug strategy for cancer cell-specific targeting: A recent overview.
Zhang X; Li X; You Q; Zhang X
Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
[TBL] [Abstract][Full Text] [Related]
17. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
Tietze LF; Krewer B
Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
[TBL] [Abstract][Full Text] [Related]
18. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
